CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 397 filers reported holding CRISPR THERAPEUTICS AG in Q4 2022. The put-call ratio across all filers is 0.90 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $227 | -71.1% | 5 | -64.3% | 0.00% | – |
| Q2 2023 | $786 | -53.0% | 14 | -62.2% | 0.00% | – |
| Q1 2023 | $1,674 | +24.8% | 37 | +12.1% | 0.00% | – |
| Q4 2022 | $1,341 | +34.1% | 33 | +94.1% | 0.00% | – |
| Q3 2022 | $1,000 | -50.0% | 17 | -54.1% | 0.00% | – |
| Q2 2022 | $2,000 | -33.3% | 37 | -32.7% | 0.00% | – |
| Q1 2022 | $3,000 | +50.0% | 55 | +175.0% | 0.00% | – |
| Q4 2021 | $2,000 | -50.0% | 20 | -31.0% | 0.00% | -100.0% |
| Q1 2021 | $4,000 | -50.0% | 29 | -42.0% | 0.00% | -50.0% |
| Q4 2020 | $8,000 | +700.0% | 50 | +400.0% | 0.00% | – |
| Q3 2020 | $1,000 | -50.0% | 10 | -81.8% | 0.00% | -100.0% |
| Q3 2019 | $2,000 | 0.0% | 55 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $2,000 | +100.0% | 55 | 0.0% | 0.00% | – |
| Q1 2019 | $1,000 | 0.0% | 55 | 0.0% | 0.00% | – |
| Q4 2018 | $1,000 | – | 55 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 508,558 | $82,330,000 | 27.28% |
| Valiant Capital Management, L.P. | 307,700 | $49,814,000 | 3.74% |
| NEA Management Company, LLC | 1,590,002 | $257,405,000 | 3.35% |
| NIA IMPACT ADVISORS, LLC | 39,891 | $6,458,000 | 3.15% |
| Ikarian Capital, LLC | 200,000 | $32,379,000 | 2.62% |
| Soleus Capital Management, L.P. | 103,114 | $16,693,000 | 2.57% |
| HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 157,334 | $25,471,000 | 2.47% |
| Capital Impact Advisors, LLC | 45,440 | $7,356,000 | 2.37% |
| ARK Investment Management | 7,776,119 | $1,258,876,000 | 2.34% |
| Sassicaia Capital Advisers LLC | 13,513 | $2,188,000 | 2.28% |